At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01177 SINO BIOPHARM
Market Closed 03-13 16:08:20
5.950
-0.080
-1.33%
High6.050Low5.930Vol33.43M
Open6.030D1 Closing6.030Amplitude1.99%
Mkt Cap111.63BTradable Cap111.63BTotal Shares18.76B
T/O200.12MT/O Rate0.18%Tradable Shares18.76B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Sino Biopharmaceutical Stock Slides 1.3% in Hong Kong, Underperforms Competitors
Dow Jones  ·  03-13 16:43
Sino Biopharmaceutical Stock Slides 1.3% in Hong Kong, Underperforms Competitors
Sino Biopharmaceutical Unit's Biliary Tract Cancer Drug Trial Reaches Primary Endpoints of Survival
MT Newswires Live  ·  03-12 19:30
Sino Biopharmaceutical Unit's Biliary Tract Cancer Drug Trial Reaches Primary Endpoints of Survival
BRIEF-Sino Biopharmaceutical Reports Positive Results On Phase III Clinical Study Of TQB3454 IDH1 Inhibitor
Reuters  ·  03-12 18:31
BRIEF-Sino Biopharmaceutical Reports Positive Results On Phase III Clinical Study Of TQB3454 IDH1 Inhibitor
SINO BIOPHARM (01177) achieves first-in-China Phase III success for IDH1 inhibitor TQB3454; NMPA filing imminent
Bulletin Express  ·  03-12 17:05
SINO BIOPHARM (01177) achieves first-in-China Phase III success for IDH1 inhibitor TQB3454; NMPA filing imminent
Thailand's Wealthiest Family Prepares Another IPO
Deep News  ·  03-12 17:02
Thailand's Wealthiest Family Prepares Another IPO
Sino Biopharmaceutical - Positive Results on Phase Iii Clinical Study of Tqb3454 Idh1 Inhibitor for Biliary Tract Cancer
THOMSON REUTERS  ·  03-12 17:01
Sino Biopharmaceutical - Positive Results on Phase Iii Clinical Study of Tqb3454 Idh1 Inhibitor for Biliary Tract Cancer
BRIEF-Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 Approved By NMPA
Reuters  ·  03-11
BRIEF-Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 Approved By NMPA
Clinical Trial for SINO BIOPHARM's (01177) TQB3205 Pan-KRAS Inhibitor Receives NMPA Approval
Stock News  ·  03-11
Clinical Trial for SINO BIOPHARM's (01177) TQB3205 Pan-KRAS Inhibitor Receives NMPA Approval
Sino Biopharmaceutical wins NMPA clinical trial approval for pan-KRAS inhibitor TQB3205
Reuters  ·  03-11
Sino Biopharmaceutical wins NMPA clinical trial approval for pan-KRAS inhibitor TQB3205
SINO BIOPHARM (01177) Secures NMPA Green Light for Clinical Trial of Pan-KRAS Inhibitor TQB3205
Bulletin Express  ·  03-11
SINO BIOPHARM (01177) Secures NMPA Green Light for Clinical Trial of Pan-KRAS Inhibitor TQB3205
Sino Biopharmaceutical - Tqb3205 Pan-Kras Inhibitor Receives Nmpa Clinical Trial Approval for Advanced Malignant Tumors
THOMSON REUTERS  ·  03-11
Sino Biopharmaceutical - Tqb3205 Pan-Kras Inhibitor Receives Nmpa Clinical Trial Approval for Advanced Malignant Tumors
Sino Biopharmaceutical Stock Falls 1.3% in Hong Kong
Dow Jones  ·  03-11
Sino Biopharmaceutical Stock Falls 1.3% in Hong Kong
Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Sanofi Rovadicitinib Licensing Agreement
Simply Wall St.  ·  03-09
Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Sanofi Rovadicitinib Licensing Agreement
Sino Biopharmaceutical Stock Climbs 3.5% in Hong Kong, Outperforms Competitors
Dow Jones  ·  03-05
Sino Biopharmaceutical Stock Climbs 3.5% in Hong Kong, Outperforms Competitors
Hong Kong Healthcare Stocks Rebound Strongly: Innovative Drug ETF Surges Over 3%
Deep News  ·  03-05
Hong Kong Healthcare Stocks Rebound Strongly: Innovative Drug ETF Surges Over 3%
Stock Track | SINO BIOPHARM Soars 6.83% Intraday on $1.53 Billion Licensing Deal with Sanofi
Stock Track  ·  03-05
Stock Track | SINO BIOPHARM Soars 6.83% Intraday on $1.53 Billion Licensing Deal with Sanofi
SINO BIOPHARM Shares Surge Over 5% on $1.53 Billion Licensing Deal with Sanofi for Rovadicitinib
Stock News  ·  03-05
SINO BIOPHARM Shares Surge Over 5% on $1.53 Billion Licensing Deal with Sanofi for Rovadicitinib
Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals
Dow Jones  ·  03-04
Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals
Sino Biopharmaceutical Limited (1177) Announces Exclusive License Agreement with Sanofi
Bulletin Express  ·  03-04
Sino Biopharmaceutical Limited (1177) Announces Exclusive License Agreement with Sanofi
Sino Biopharm Inks Exclusive Licensing Deal with Sanofi for Rovadicitinib
Stock News  ·  03-04
Sino Biopharm Inks Exclusive Licensing Deal with Sanofi for Rovadicitinib

Introduction

Company Name.
SINO BIOPHARM
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sino Biopharmaceutical Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company operates its business through three segments. The Modernised Chinese Medicines and Chemical Medicines segment is mainly engaged in the manufacture, sale and distribution of modernised Chinese medicine products and western medicine products. The Investment segment is mainly engaged in the long term investments business. The Others segment is mainly engaged in the related healthcare and hospital business.
Issue price:
--